Lecanemab (Leqembi) and Donanemab (Kisunla) are the two fully FDA-approved anti-amyloid monoclonal antibodies shown to slow Alzheimer's progression, with Aducanumab (Aduhelm) also approved but with mixed trial outcomes.
Open the full topic